NewAmsterdam Pharma announced the pricing of its upsized public offering, which is expected to generate approximately $416.5 million in gross proceeds. The offering includes 12,117,347 ordinary shares priced at $24.50 per share and 4,882,653 pre-funded warrants at $24.4999 per warrant.
The company also granted the underwriters a 30-day option to purchase up to an additional 2,550,000 ordinary shares at the public offering price. This upsized offering reflects strong investor interest in NewAmsterdam Pharma's pipeline and future prospects.
The offering is expected to close around December 13, 2024, subject to customary closing conditions. The additional capital will support the company's ongoing clinical development programs and commercialization preparations for obicetrapib.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.